Journal article
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200 †
Abstract
BACKGROUND: A subgroup of sarcomas is characterized by defining chromosomal translocations, creating fusion transcription factor oncogenes. Resultant fusion oncoproteins associate with chromatin-modifying complexes containing histone deacetylases (HDAC), and lead to epigenetic transcriptional dysregulation. HDAC inhibitors were shown to be effective in vitro, reversing gene repression by these complexes, restoring PTEN expression and apoptosis …
Authors
Chu QS-C; Nielsen TO; Alcindor T; Gupta A; Endo M; Goytain A; Xu H; Verma S; Tozer R; Knowling M
Journal
Annals of Oncology, Vol. 26, No. 5, pp. 973–981
Publisher
Elsevier
Publication Date
May 2015
DOI
10.1093/annonc/mdv033
ISSN
0923-7534
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Administration, OralAdultAntineoplastic AgentsBenzimidazolesBiomarkers, TumorCanadaDisease ProgressionDisease-Free SurvivalDrug Administration ScheduleEarly Termination of Clinical TrialsFemaleHistone Deacetylase 2Histone Deacetylase InhibitorsHumansMaleMiddle AgedNeoplasm Recurrence, LocalSarcomaTime FactorsTranslocation, GeneticTreatment OutcomeYoung Adult